PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.

The current study shows that these patients may have a good response to platinum-based chemotherapy and a favorable survival. And these patients can benefit from PARPis treatment and will likely be suitable candidates for PARPis.